Primary Objective: \- To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings. Secondary Objective: * To describe the demographic and clinical characteristics of patients with symptomatic VTE including characteristics of VTE, VTE risk factors and bleeding risk factors. * To assess the frequency of patient characteristics that would necessitate adjustment in the dose or duration of enoxaparin therapy, e.g. high BMI, impaired creatinine clearance, advanced age, cancer-associated VTE. * To assess the degree of adherence in clinical practice to Consensus Guidelines (ACCP/American College of chest Physician 2008) for the management of acute VTE, vis a vis: * Appropriate dosing of enoxaparin * Recommended duration of initial LMWH therapy * Adequate overlap of LMWH with vitamin K antagonists (VKA) * Recommended duration of longterm VKA * Frequency of use of LMWH monotherapy to treat cancer-related VTE * To access safety outcomes (including bleeding and recurrent VTE) * To describe the utilization of resources due to bleeding and recurrent VTE during the treatment period.
Study Type
OBSERVATIONAL
Enrollment
915
Sanofi-Aventis Administrative Office
Laval, Canada
Proportion of patients with Deep Venous Thrombosis (DVT) and/or Pulmonary Embolism (PE) and/or thrombosis at unusual sites
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
Number of patients prescribed twice daily (BID) vs. once daily (QD) enoxaparin
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
Proportion of patients who used short (5-7 days) vs. longer use (more than 7 days) durations of treatment with enoxaparin
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
Percentage of exnoxaparin prefilled syringes vs. multidose vials used during treatment
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
Patient characteristics associated with different patterns of VTE management and enoxaparin use
Analysis of patient characteristics associated with different patterns of VTE management and enoxaparin use, such as age, weight, creatinine clearance, co-morbid disease, VTE characteristics, concomitant use of other pharmacological and non-pharmacological treatment of the VTE, concomitant use of other non-VTE related therapies
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
Percentage of cases managed as recommended by Concensus Guidelines (ACCP 2008)
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
Incidence of bleeding events and episodes of recurrent VTE
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
To tabulate VTE-related resources utilized during the study period and compare resource utilization in patients treated vs not treated as per Concensus Guidelines (ACCP 2008)
VTE-related resources utilized during the study period, including cost of VTE and its treatment (e.g. duration of hospital stay, drug costs, costs related to bleeding such as transfusions, costs of recurrent VTE) and compare resource utilization in patients treated vs. not treated as recommended by Concensus Guidelines (ACCP 2008)
Time frame: Day 180 or end of anticoagulant therapy whichever comes first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.